Drugs prescription for osteoporosis;Utilización de fármacos para la osteoporosis

Anales del Sistema Sanitario de Navarra

Volumn 26, Issue SUPPL. 3, 2003, Pages 107-121

  López, Juan Erviti ^a,b  

^a Instituto de Investigación Sanitaria de Navarra   (Spain)

^b NONE   (Spain)

Author keywords

Biphosphonates; Calcitonin; Hormone replacement therapy; Osteoporosis; Raloxifen

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; RALOXIFENE;

ARTICLE; CALCIUM INTAKE; DOSE RESPONSE; DRUG EFFICACY; DRUG USE; EVOLUTION; HIP FRACTURE; HISTORY OF MEDICINE; HORMONE SUBSTITUTION; HUMAN; MEDICAL SPECIALIST; OSTEOPOROSIS; SPAIN; STATISTICAL SIGNIFICANCE; SUMMER; WINTER;

CALCITONIN; DIETARY SUPPLEMENTS; DIPHOSPHONATES; DRUG UTILIZATION; ESTROGEN REPLACEMENT THERAPY; HUMANS; OSTEOPOROSIS; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SPAIN;

EID: 0742301301     PISSN: 11376627     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Consensus Development Conference: diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993; 94: 646-650.
2. ARBOLEYA LR, CASTRO MA, BARTOLOMÉ E, GERVAS L, VEGA R. Epidemiología de la fractura osteoporótica de cadera en la provincia de Palencia. Rev Clin Esp 1997; 197: 611-617.
3. IZQUIERDO M, OCHOA C, SÁNCHEZ I, HIDALGO H, LOZANO DEL VALLE F, MARTÍN R. Epidemiología de la fractura osteoporótica de cadera en la provincia de Zamora (1993). Rev Esp Salud Pública 1997; 71: 357-367.
4. TOGERSON DJ, BELL-SYER SE. Hormone replacement therapy and prevention of nonvertebral fractures. A meta-analysis of randomized trials. JAMA 2001; 285: 2891-2897.
5. BINDER EF, WILLIAMS DB, SCHECHTMAN KB, JEFFE DB, KOHRT WM. Effects of hormone replacement therapy on serum lipids in elderly women. A randomized, placebo-controlled trial. Ann Intern Med 2001; 134; 754-760.
6. HULLEY S, GRADY D, BUSH T, FURBERG C, HERRINGTON D, RIGGS B et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women (HERS). Research Group. JAMA 1998; 280: 605-613.
7. GRADY D, HERRINGTON D, BITTNER V, BLUMENTHAL R, DAVIDSON M, HLATKY M et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/ progestin replacement study follow-up (HERS II). JAMA 2002; 288: 49-57.
8. HULLEY S, FURBERG C, BARRETT-CONNOR E, CAULEY J, GRADY D, HASKELL W et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 2002; 288: 58-66.
9. Women's Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's health initiative randomized controlled trial. JAMA 2002; 288: 321-333.
10. VONGPATANASIN W, TUNCEL M, WANG Z, ARBIQUE D, MEHRAD B, JIALAL I. Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. J Am Coll Cardiology 2003; 41: 1358-1363.
11. ETTINGER B, BLACK DM, MITLAK BH, KNICKERBOCKER RK, NICKELSEN T, GENANT HK et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3 year randomized clinical trial. JAMA 1999; 282: 637-645.
12. BARRETT-CONNOR E, GRADY D, SASHEGYI A, ANDERSON PW, COX DA, HOSZOWSKI K et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002; 287: 847-857.
13. STORM T, THAMSBORG G, STEINICHE T, GENENT HK, SORENSEN OH. Effect of intermitent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990; 322: 1265-1271.
14. HARRIS ST, WATTS NB, JACKSON RD, GENENT HK, WASNICH RD, ROSS P et al. Four-year study of intermitent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 1993; 95: 557-567.
15. LIBERMAN UA, WEISS SR, BROLL J, MINNE HW, HUI Q, BELL N et al. Effects of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437-1443.
16. BLACK DM, CUMMINGS SR, KARPF DB, CAULEY JA, THOMPSON DE, NEVITT MC et al. Randomised trial of effect of alendronate on risk fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-1541.
17. CUMMINGS SR, BLACK DM, THOMPSON D, APPLEGATE WB, BARRET-CONNOR E, MUSLINER T et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the fracture intervention trial. JAMA 1998; 280: 2077-2082.
18. ARBOLEYA LR, MORALES A, FITER J. Efecto del alendronato sobre la densidad mineral ósea y la incidencia de fracturas en mujeres posmenopáusicas con osteoporosis. Un metaanálisis de los estudios publicados. Med Clin (Barc) 2000; 114 (Supl 2): 79-84.
19. RODRIΝGUEZ C, FIDALGO ML, RUBIO S. Análisis coste-efectividad de alendronato frente a placebo en la prevención de fractura de cadera. Aten Prim 1999; 24: 390-396.
20. BONE HG, DOWNS RW, TUCCI JR, HARRIS ST, WEINSTEIN R, LICATA AA et al. Dose-response relationships for alendronate treatment in osteoporotic elderly women. J Clin Endocrinol Metab 1997; 82: 265-274.
21. HARRIS ST, WATTS NB, GENENT HK, MCKEEVER CD, HANGARTNER T, KELLER M et al. Effects of risedronate treatment on vertebral and non vertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999; 282: 1344-1352.
22. REGINSTER JY, MINNE HW, SORENSEN OH, HOOPER M, ROUX C, BRANDI ML et al. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporosis Int 2000; 11: 83-91.
23. MCCLUNG MR, GEUSENS P, MILLER PD, ZIPPEL H, BENSEN WG, ROUX C et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 344: 333-340.
24. LANZA FL, SCHWARTZ H, SAHBA B, MALATY HN, MUSLINER T, REYES R et al. An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae. Am J Gastroenterol 2000; 95: 31112-31117.
25. LANZA FL, HUNT RH, THOMSON AB, PRVENZA JM, BLANK MA. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 2000; 119: 631-638.
26. CHESNUT CH, SILVERMAN S, ANDRIANO K, GENENT H, GIMONA A, HARRIS S et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 2000; 109: 267-276.
27. CUMMINGS SR, CHAPURLAT RD. What PROOF proves about calcitonin and clinical trials [editorial]. Am J Med 2000; 109: 330-331.
28. VALECILLO G, DÍEZ A, CARBONELL J, GONZÁLEZ J. Tratamiento de la osteoporosis con calcio y vitamina D. Revisión sistemática. Med Clin (Barc) 2000; 115: 46-51.
29. CHAPUY MC, ARLOT ME, DELMAS PD, MEUNIER PJ. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. Brit Med J 1994; 308: 1081-1082.
30. DAWSON-HUGHES B, HARRIS SS, KRALI EA, DALLAL GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337: 670-676.